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Abstract
Background & Aims—The interferon-free regimen of simeprevir plus sofosbuvir was 
recommended by professional guidelines for certain patients with hepatitis C virus (HCV) 
genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and 
efficacy of this regimen in clinical practice settings in North America.
Methods—We collected demographic, clinical, and virologic data, as well as reports of adverse 
outcomes, from sequential participants in HCV-TARGET—a prospective, observational cohort 
study of patients undergoing HCV treatment in routine clinical care settings. From January 
through October 2014, 836 patients with HCV genotype 1 infection began 12 weeks of treatment 
with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients 
received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had 
cirrhosis. Most had failed prior treatment with peginterferon and ribavirin without (46%) or with 
telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), 
defined as level of HCV RNA below quantification at least 64 days after the end of treatment 
(beginning of week 12 after treatment—a 2 week window). Logistic regression models with 
inverse probability weights were constructed to adjust for baseline covariates and potential 
selection bias.
Results—The overall rate of SVR rate was 84% (675/802 patients, 95% CI: 81–87%). Model-
adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease 
inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no 
detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, 
and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% 
of participants, respectively.
Conclusions—In a large, prospective observational cohort study, a 12 week regimen of 
simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment 
discontinuation. ClinicalTrials.gov: NCT01474811
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Introduction
Globally, chronic hepatitis C virus (HCV) is a major cause of morbidity and mortality, 
infecting an estimated 170 million persons.1, 2 Successful treatment results in cure of HCV, 
which has been linked to significant reductions in the risk of HCV-related complications 
including liver failure, hepatocellular carcinoma, need for transplantation and death.3–5 Until 
recently, the effectiveness of interferon-based treatments for HCV genotype 1 has been 
substantially limited by host-dependent HCV suppression and by significant safety and 
tolerability issues.6, 7 As many as 60% of patients evaluated in real world settings have been 
considered ineligible for HCV treatment with such interferon containing regimens.6, 8 
Importantly, patients with advanced liver disease or decompensated cirrhosis were among 
those patients in whom the effectiveness of interferon-based therapy has been severely 
limited.9
In early 2014, the first highly effective, interferon-sparing HCV treatment regimen, 
simeprevir plus sofosbuvir entered clinical practice in the United States for the treatment of 
patients with HCV genotype 1 infection.10–12 In the phase 2 COSMOS study, this regimen 
was investigated with and without ribavirin for durations of 12 and 24 weeks in treatment 
naïve and prior null responders to peginterferon/ribavirin. Overall, more than 95% of the 
167 patients treated in the COSMOS study achieved SVR and the addition of ribavirin did 
not appear to increase the likelihood of SVR. Based on the findings of this study, the 
American Association for the Study of Liver Disease (AASLD) and the Infectious Diseases 
Society of America (IDSA) HCV Guidance Panel recommended the interferon-free, oral 
combination of simeprevir plus sofosbuvir with or without ribavirin for 12 weeks for the 
treatment of patients with chronic HCV infection who cannot take interferon and for those 
for whom prior treatment with peginterferon/ribavirin was ineffective.13 In the context of 
significant unmet medical need, the combination of simeprevir plus sofosbuvir as two pills 
once daily was rapidly adopted for the treatment of patients with HCV genotype 1 infection 
in North America.
The translation of novel HCV therapeutics from clinical trials to clinical practice has been 
associated with substantially lower SVR rates and higher rates of adverse events than 
observed in clinical trials.14, 15 Thus, the present study analyzed data from the HCV-
TARGET, an observational cohort study designed to evaluate the safety, tolerability and 
effectiveness of simeprevir plus sofosbuvir in patients undergoing HCV treatment in routine 
clinical care settings.
Patients
HCV-TARGET is a consortium of academic (n=39) and community (n=15) centers that 
provide medical care and antiviral treatment to HCV-infected patients. Since 2011, patients 
prescribed HCV treatment as part of routine clinical practice have been enrolled in a 
longitudinal, prospective observational cohort study. In the current study, data from 
sequential patients treated with the interferon-free, combination of simeprevir plus 
sofosbuvir were prospectively collected within a centralized database utilizing standardized 
source data abstraction as previously described14 and managed using Research Electronic 
Data Capture (REDCap) electronic data capture tools hosted at UNC Chapel Hill. REDCap 
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is a secure, web-based application designed to support data capture for research studies16. 
Patients were eligible if they were 18 years old or greater and were treated with the oral 
regimen with or without ribavirin. The cohort of patients included in this analysis started 
treatment prior to 10 October 2014, were infected with HCV genotype 1, did not have a 
prior liver transplantation, and were on treatment less than 16 weeks. During the study 
period, an additional 300 patients meeting these criteria were treated with alternative HCV 
regimens including sofosbuvir plus ribavirin alone (n=11) or with peginterferon (n=282). 
These patients were not included in the analysis since these alternatives were not potent, 
interferon-free HCV regimens. In light of the rapidly changing treatment options for HCV, 
the inclusion window for this cohort was defined a priori without reference to power/sample 
size calculations in order to provide a timely description of efficacy and safety of simeprevir 
plus sofosbuvir in clinical practice settings.
Treatments
The decision to initiate HCV treatment and the selection of the HCV treatment regimen 
(with or without ribavirin) was solely the responsibility of the treating clinician and his or 
her patient; this was a non-random process in which a regimen was selected for an 
individual patient. Patients were treated with sofosbuvir administered as a single 400 
milligram tablet taken by mouth daily and simeprevir administered as a single 150 milligram 
capsule taken by mouth daily. Ribavirin dosing was variable across patients and treatment 
centers; however, for most patients, ribavirin was administered according to body weight (< 
75 kilograms, 1000 milligrams/day in two divided doses; ≥ 75 kilograms, 1200 
milligrams/day in two divided doses). The duration of HCV therapy for all patients in this 
analysis was 12 weeks with post-treatment follow-up of at least 64 days.
Measurements
Demographic, clinical, adverse events and virologic data were collected throughout 
treatment and post-treatment follow-up. Routine laboratory data collected included levels of 
serum creatinine, albumin, total bilirubin, alanine and aspartate aminotransferase, INR, 
hemoglobin, platelet count and HCV RNA. Liver disease stage (cirrhosis or no cirrhosis) 
was defined at the time of enrollment by biopsy and/or imaging and clinical criteria 
established a priori.14 The criteria for the diagnosis of cirrhosis were either confirmation by 
staging liver biopsy or a combination of clinical, laboratory, histologic, and imaging criteria 
features. Patients with METAVIR stage 3 fibrosis by liver biopsy, were defined as cirrhotic 
if they had any of the following: platelet count <140,000 per µL, presence of esophageal 
varices on esophagogastroduodenoscopy, nodular liver, portal hypertension, or ascites by 
radiologic imaging, non-invasive serum panels such as FibroSURE® (Laboratory 
Corporation of America) consistent with stage 4 fibrosis, or liver stiffness measurement by 
elastography (FibroScan®) with consistent with stage 4 fibrosis (kPa ≥ 14).17, 18 In the 
absence of liver biopsy, cirrhosis was defined by exhibiting two or more of the above non-
histologic criteria. History of hepatic decompensation was defined as evidence of prior or 
current diagnosis of ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or 
variceal hemorrhage or baseline concomitant medications with a specific indication for 
ascites, hepatic encephalopathy, hepatic hydrothorax, spontaneous bacterial peritonitis, or 
variceal hemorrhage.
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Outcomes
Treatment efficacy was measured as sustained virologic response (SVR12) defined as HCV 
RNA level below level of quantitation or undetected recorded at least 64 days after 
treatment was discontinued. For those who did not achieve SVR, the frequency of relapse, 
virological breakthrough, and non-response was reported, as were those lost-to-follow-up or 
had early treatment discontinuations due to adverse events or other factors. Adverse events 
(AEs) were captured as follows: i) Any event that required a HCV medication dose 
reduction or discontinuation or the addition of a concomitant medication for management; 
ii) any event of special interest during treatment (e.g. rash, photosensitivity, anemia, 
jaundice, hepatic decompensation) regardless of management. Anemia was defined as 
presence of one of the following: i) anemia reported as an AE; ii) administration of red 
blood cell growth factors; or iii) blood transfusion. Serious adverse events (SAEs) were any 
AEs that met these criteria: i) Required hospitalization, or ii) met criteria for expedited 
reporting per FDA form MEDWATCH 35000.
Analysis Strategy
(1) The two treatment groups were described and compared in terms of baseline covariates. 
(2) Crude SVR rates (SVR calculated without adjustment for treatment choice or other 
covariates) and their relationships to patient characteristics were explored for each treatment 
group and for the groups combined. (3) The estimation and comparison of model-adjusted 
SVR rates relied on a two-step approach 27. In the first step, a logistic regression “selection 
model” was used to estimate the probability of treatment without ribavirin (i.e., the 
propensity score) as a function of potential confounders measured at baseline: fibrosis status, 
genotype, baseline AST, treatment start date, previous treatment with telaprevir or 
boceprevir).
In the second step, the estimated propensity scores were used to compute inverse of 
probability of treatment weights (IPTW), and the weights were used in the fitting of a 
logistic regression ‘response model’ for achievement of SVR as a function of baseline 
laboratory measures and the interaction of regimen with age, sex, cirrhosis status, HCV 
genotype/subtype 1a or 1b, previous telaprevir or boceprevir treatment failure, previous 
peginterferon/ribavirin treatment failure, and history of decompensating events. The set of 
baseline variables was selected a priori to the analysis. Standard errors for the resulting 
estimated odds ratios (ORs) were computed using the Huber-White sandwich estimator 28.
Model-adjusted estimates of SVR for sub-populations were calculated by averaging the 
patient-level estimates of SVR over the relevant sub-population. The corresponding standard 
error estimates for SVR were calculated from the standard error estimates of the odds ratios 
with numerical integration. To investigate the adequacy of the selection model, the weighted 
comparability of the two treatment groups was examined for its balance on the distributions 
of the baseline covariates. To evaluate the robustness of the main results to reasonable 
perturbations of assumptions and methods, analysis using matching as an alternative method 
for estimating treatment effects with observational data was performed.
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Missing Data
Multiple imputation methods30 were used in order to investigate the potential bias related to 
missing outcome data. For each patient missing SVR12, we constructed a pool of similar 
patients not missing SVR12 by selecting patients with the same treatment regimen, cirrhosis 
status, previous treatment experience, and history of prior decompensation. We imputed the 
missing SVR12 by randomly selecting the response from a patient in the pool of similar 
patients. In order to incorporate information from the available post treatment HCV RNA 
measures, we gave a greater selection probability to patients in the pool whose post-
treatment HCV RNA measures more closely resembled the available post-treatment HCV 
RNA measures of the patient missing SVR12. We generated 25 imputed datasets with this 
procedure. Estimates of SVR12 and estimates of odds ratios involving SVR12 were 
calculated by analyzing individually the 25 dataset and then combining the results into a 
single estimate and associated standard error using multiple imputation methods.31 To 
investigate the adequacy of the imputation model, the estimates of SVR12 to two other 
SVR12 estimates were compared: (a) the ‘complete-case’ estimate in which observations 
with missing SVR12 were omitted and (b) the ‘worst-case scenario’ estimate in which 
observations with missing SVR12 were marked as failures. The multiply imputed estimates 
appeared to be adequate.
Informed Consent
The protocol was conducted in accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines. The independent ethics committee at each participating study 
center or a central IRB approved the protocol if a local IRB was not in place. All patients 
provided written informed consent for their participation. All authors had complete access to 
the study data, reviewed and approved the final manuscript.
Results
Patient population
Between January 1, 2014 and October 10, 2014, 836 patients with chronic HCV genotype 1 
without history of liver transplant initiated treatment with simeprevir plus sofosbuvir for 12 
weeks; of whom, 169 patients received concurrent ribavirin. The majority of patients were 
males (n=509, 60.9%), Caucasian (n=638; 76.3%) or Black (n=112; 13.4%), and between 
the ages 40 and 64 years (n=603; 72.1%) or older than 65 (n=204, n=24.4%) (Table 1). HCV 
genotype 1a and 1b infection was present in 60.9% and 28.9%, respectively; of note, 
subtype was not reported in 10.2% of patients. Testing for the presence of HCV variants 
with the Q80K polymorphism prior to treatment was performed in only 90 patients (10.7%). 
At baseline, cirrhosis was found in 491 patients (58.7%); of whom, 45% (n=221) had a prior 
episode of hepatic decompensation and 141 (40.3% of those with available scores) had a 
pre-treatment MELD score greater than or equal to 10. A high proportion of patients had 
previously failed to respond to treatment with peginterferon plus ribavirin (n=387, 46.3%), 
and 12% (n=100) had failed to respond to treatment that included first generation protease 
inhibitors, telaprevir or boceprevir. At baseline, the clinical and demographic characteristics 
of patients who received ribavirin were similar to those who were not prescribed ribavirin 
(Table 1).
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Efficacy
Outcomes were available for 802 of 836 patients (including 32 patients lost to follow-up) 
who started therapy with simeprevir plus sofosbuvir. Of those, 675 patients (84.2%) 
achieved SVR12. Of the patients who failed to achieve SVR12, the most frequent reason for 
not achieving SVR was post-treatment relapse (n=91 of 127 failures). In addition, three 
patients had lack of efficacy during treatment (2.4% of 127 failures) and 30 were lost to 
follow up after completing treatment (24% of 127 failures) (Table 2). An additional 34 
patients (4%) remain in post treatment follow up. The SVR12 rate was similar in persons 
who received ribavirin (132 of 163 patients, 81%) and those who did not receive ribavirin 
(543 of 639 patients, 85%) (Table 3).
Among patients with outcomes available (n=802), the crude SVR12 rate varied according to 
the presence or absence of baseline cirrhosis, prior treatment experience, and subtype 1a or 
1b (Table 3). In patients with genotype 1a infection treated with simeprevir plus sofosbuvir 
the crude SVR12 rate was 83% (308 of 371 patients) and 82% (102 of 125 patients) for 
patients who received this combination plus ribavirin. The crude SVR12 rate in patients with 
genotype 1b infection treated with simeprevir plus sofosbuvir without ribavirin was 90% 
(185 of 206 patients) and 84% (16 of 19 patients) with use of ribavirin. The highest crude 
SVR12 rates were observed among patients who were treatment-naïve, non-cirrhotic and 
infected with genotype 1b (39 of 40 patients, 98%) whereas the lowest crude SVR12 rates 
were observed patient who were treatment-experienced, cirrhotic and infected with genotype 
1a (138 of 179, 77%) (Table 3).
The SVR rates (estimated with multiple imputation methods to account for missing 
outcomes) among patients categorized by each of these factors (cirrhosis/no cirrhosis; 
treatment-naïve/treatment experienced and subtype 1a/1b) and other populations of interest, 
such as prior failures of protease inhibitors are shown in Figure 1a (overall population), 
Figure 1b (with ribavirin) and 1c (without ribavirin). In patients who completed treatment or 
discontinued early due to lack of efficacy, the SVR12 rate was lower among patients with 
cirrhosis compared to those without cirrhosis, higher in treatment naïve patients compared to 
those who had been treated previously and did not vary according to the use of ribavirin. 
The estimated SVR rates for patients who failed to respond to prior protease inhibitor-based 
regimens were 72% (95% CI: 55, 85) and 81% (95% CI: 69, 89) for simeprevir plus 
sofosbuvir with or without ribavirin, respectively. Due to limited pre-treatment testing, the 
impact of the presence of the Q80K or other baseline resistance associated variants could not 
be assessed.
In the comparison of the two treatment regimens in terms of the model-adjusted SVR12 
rates (with inverse probability of treatment weighting and adjusting for baseline factors), the 
overall SVR12 rate for patients treated without ribavirin was similar to those treated with 
ribavirin; the estimated difference in SVR12 was −2.3% (95%CI: −10.1, 6.4). Further, the 
difference in SVR rates for with and without ribavirin was similar (varying by no more than 
± 6%) in a variety of subpopulations such as patients with cirrhosis versus no cirrhosis, 
genotype 1a versus 1b infection, treatment naïve versus experienced, or combinations of two 
of these factors. (Figure 2).
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In exploratory analyses of the two groups combined with covariate adjustment for treatment 
regimen, genotype, gender, and age, several baseline patient and/or disease characteristics 
exhibited association with lower likelihood of SVR. The estimates suggest that patients with 
cirrhosis or historical evidence of hepatic decompensation and those with prior non-response 
following treatment with HCV protease inhibitors, telaprevir or boceprevir were less likely 
to achieve SVR. Further, the exploratory analysis indicates that higher total bilirubin or 
higher aspartate aminotransferase may be associated with lower SVR rates. In contrast, 
patients with higher baseline serum levels of albumin, total platelet count and hemoglobin 
were more likely to have an SVR. Interestingly, after adjusting for regimen, gender, and age, 
the estimate of association between genotype/subtype (1a versus 1b infection) and SVR was 
not as precise as the crude association discussed earlier (Figure 3).
Safety and tolerability
Ninety seven percent of patients completed the prescribed treatment course. Discontinuation 
of simeprevir plus sofosbuvir with or without ribavirin occurred in only 25 patients (3%), 
and the rate of discontinuation for adverse events was only 2% (Table 2). The 
discontinuation rate for adverse events was similar in patients taking ribavirin (2.4%) and in 
those taking simeprevir plus sofosbuvir alone (1.9%). During the course of observation, five 
deaths were observed (Table 4); two deaths due to hepatic failure occurred in patients with 
advanced liver disease, and one death each was reported due to cerebral vascular accident, 
vascular shock, and unknown causes. Serious adverse events were recorded in 44 patients 
(5.3%), and incidence of such events was similar in patients taking or not taking ribavirin 
(7.1% and 4.8% respectively). Notable serious adverse events included gastrointestinal 
bleeding in 4 patients (0.5%), hepatic failure or encephalopathy in 10 patients (1.2%), 
infections in 9 patients (1.1%). No serious adverse events related to skin rash or 
photosensitivities were reported; however, one patient stopped simeprevir plus sofosbuvir 
alone due to photosensitivity.
The majority of serious adverse events occurred in patients with cirrhosis at baseline (37 of 
44 reported events, 84%). Ten patients with cirrhosis underwent liver transplantation during 
the treatment period and all remained HCV RNA uninfected post-transplant. Approximately 
40% of patients with cirrhosis and laboratory data available had a MELD score greater than 
10 prior to therapy (n=141). Among those with repeat MELD determination during 
treatment, only 35 (19%) had an increase in MELD, and the majority were stable or 
decreased.
In overall population the most common adverse events were fatigue, headache, nausea, flu 
like symptoms, rash/ pruritus and insomnia (Table 4). Fatigue was reported in 222 patients 
(26.5%), and was more common in patients taking ribavirin (36%) compared to those taking 
simeprevir plus sofosbuvir alone (24%). Photosensitivity was observed in 58 patients (7%) 
and the incidence was similar in persons with and without ribavirin exposure. Patients taking 
ribavirin were more likely to develop anemia (29.6%) compared to patients not taking 
ribavirin (1.2%). The mean change in hemoglobin from baseline levels to on-treatment nadir 
was −2.1 grams/dL in patients taking ribavirin compared to −0.4 grams/dL in those taking 
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only simeprevir plus sofosbuvir. Blood transfusions and use of erythropoietin agonists were 
uncommon.(Table 4).
Discussion
Following the individual regulatory approval of sofosbuvir, a nucleoside analogue NS5B 
polymerase inhibitor, and simeprevir, a NS3 protease inhibitor, each in combination with 
peginterferon/ribavirin, the AASLD/IDSA guidance panel provided recommendations for 
treatment of HCV with the “off-label” combination of these oral antivirals in patient for 
whom interferon was ineffective or contraindicated. In this context, more than 800 patients 
with HCV genotype 1 infection treated with the interferon-free, once-daily, oral combination 
of simeprevir and sofosbuvir were prospectively enrolled in the HCV TARGET prospective 
cohort study. Consistent with the recommendations by this panel, the majority of patients 
treated in the cohort study had an urgent need for HCV treatment, characterized by cirrhosis 
(58.7%) and non-response to prior therapy (61%). In this setting, the oral combination of 
simeprevir plus sofosbuvir was well tolerated, with only ∼ 2% of patients discontinuing 
treatment due to adverse events. Further, following 12 weeks regimen with (20%) or without 
ribavirin (80%), HCV cure was achieved in 84% of patients, many of whom had no options 
for effective HCV treatment prior to availability of these drugs. The successful translation of 
this novel, oral combination regimen from the clinical trial setting to clinical practice has 
several important implications for expectations the era of interferon-free therapy.
The AASLD/IDSA panel recommendation for use of this oral regimen in patients ineligible 
for interferon and those who had failed prior therapies was based on the absence of drug 
interactions between these antivirals and a relatively small (n=167) phase 2 COSMOS study 
in which this combination with and without ribavirin was examined for 12 or 24 weeks 
duration for the treatment of HCV genotype 1-infected patients including peginterferon/
ribavirin experienced patients with compensated cirrhosis. In the final analysis of the phase 
2 COSMOS study, Lawitz and coworkers report that simeprevir plus sofosbuvir was well 
tolerated and associated with high rates of SVR in all patient groups, and response rates 
were similar with or without ribavirin and with 12 or 24 weeks of therapy.10 More recently, 
the combination of simeprevir plus sofosbuvir was evaluated in two phase 3 clinical trials in 
HCV genotype 1 infected patients with (OPTIMIST-2 study) and without cirrhosis 
(OPTIMIST-1 study). Among patients treated for 12 weeks, SVR12 was achieved in 83% of 
103 patients with compensated cirrhosis and 97% of patients with no evidence of 
cirrhosis.19, 20 Interestingly, the findings from these phase 3 studies were not available to the 
AASLD/IDSA panel members when recommendations to use the combination of simeprevir 
pus sofosbuvir were first published in January 2014. Since many of the patients treated in 
clinical practice settings may fall outside the spectrum of those patients treated in clinical 
trials, the translation from trials to community may be associated with a substantial decrease 
in clinical effectives as was the case with telaprevir or boceprevir in combination with 
peginterferon/ribavirin.15, 21, 22
Indeed, many of the patients enrolled in this HCV TARGET cohort would likely not have 
met enrollment criteria for the phase 2 and 3 studies due to prior hepatic decompensation 
(n=233) or prior treatment with NS3 protease inhibitors (n=100). Overall, the crude SVR 
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rate among patients with cirrhosis was 81% and, although the SVR rate was lower among 
patients with prior hepatic decompensation (75%), those patients had no safe options for 
treatment prior to the availability of these combinations. Despite population with more 
advanced disease, this SVR rate is similar to that observed in patient with compensated 
cirrhosis in the OPTIMIST-2 study. Of equal importance, discontinuation due to adverse 
events and serious adverse advents was uncommon in this relatively unstable group of 
patients. Nonetheless, we did observe virologic relapse after stopping therapy in 15% of 
cirrhotic patients and 20% of those with prior decompensation (not shown in tables). This 
observation is consistent with the relatively high rate of post-treatment virologic relapse in 
patients with compensated cirrhosis treated for 12 weeks with simeprevir plus sofosbuvir in 
the OPTIMIST-2 study. In hindsight, these patients treated for 12 weeks in HCV TARGET 
may have benefited from longer treatment duration (24 weeks) as was ultimately 
recommended by the FDA based on the observation in the COSMOS study of higher rates of 
post-treatment relapse in patients with advanced fibrosis who were randomized to 12 weeks 
of treatment (3 patients with relapse) compared to those treated for 24 weeks (no patients 
with relapse).23
We also found that patients with prior exposure to HCV protease inhibitors and those with 
genotype 1a infection were less likely to achieve SVR compared to other patient 
populations. Similar to the findings reported in the phase 2 COSMOS study, the addition of 
ribavirin did not appear to increase the likelihood of SVR in this patient population. 
However, in our cohort, more than 74% of patients who had failed telaprevir or boceprevir 
plus peginterferon/ribavirin achieved SVR. This finding was somewhat unanticipated since 
the AASLD/IDSA guidance panel recommended that such patients not be treated with 
simeprevir, a NS3 protease inhibitor, due to the possibility that persistent variants selected 
and enriched by the previous protease inhibitor exposure would confer resistance to 
simeprevir.24, 25 Although not definitive, this observation supports the hypothesis that some 
HCV-infected patients who fail DAA therapy may be successfully re-treated with 
combination regimens that include antivirals that target the same HCV non-structural 
proteins as drugs included in the failed regimen.
Similarly, patients with genotype 1a infection had lower SVR rates compared to those with 
1b infection, suggesting the potential impact of baseline simeprevir resistance associated 
variants, namely the Q80K variant which is found in up to 50% of patients with genotype 1a 
infection in the US and is known to confer inferior response to simeprevir plus 
peginterferon/ribavirin.10, 12, 26 Unfortunately, baseline testing for the Q80K polymorphism 
was uncommon (∼ 10% of the cohort) which limits the ability to assess SVR in this specific 
group of patients. Recent data from the phase 3 OPTIMIST studies suggest that presence of 
Q80K was associated with a decreased response in HCV genotype 1a infected patients with 
cirrhosis treated with simeprevir plus sofosbuvir but had no impact in non-cirrhotic patients 
treated for 12 weeks.19, 20 These observations suggest that the presence of Q80K may 
explain the lower SVR rates observed in our study among patients with genotype 1a 
infection compared with 1b infection. Further studies are underway to assess baseline blood 
samples for patients in this cohort to estimate the prevalence of baseline resistance-
associated variants and their relationship with the likelihood of SVR.
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Our study is subject to several limitations. First, the absence of randomization limits our 
ability to make definitive conclusions regarding the role of ribavirin. However, our results 
suggest that the presence of ribavirin had minimal or no impact the efficacy of simeprevir-
sofosbuvir for all subgroups evaluated. Recent phase 3 trials of the combination of 
simeprevir plus sofosbuvir did not include ribavirin; as such, our analysis, in which we did 
not detect evidence of greater treatment efficacy with ribavirin, provides useful clinical data. 
Whether the addition of ribavirin to a 12 week regimen would be competitive with a 24 
week regimen of simeprevir and sofosbuvir without ribavirin, as suggested by recent studies 
of the NS5A inhibitor ledipasvir plus sofosbuvir would require further study. Second, we 
enrolled a heterogeneous patient group including some patients for whom simeprevir is not 
recommended. While this limits our ability to compare outcomes in our study to clinical trial 
settings, these data provide valuable insights into the safety, tolerability and efficacy of these 
agents in the real world. Since this cohort was enrolled, two additional HCV oral regimens 
have been approved by the FDA, although simeprevir plus sofosbuvir remains one of several 
first-line options recommended by the AASLD/IDSA HCV Guidance Panel for the 
treatment of patients with genotype 1 infection. Furthermore, the combination of sofosbuvir 
and simeprevir may be although the efficacy in this population and the roles of extended 
treatment duration and the addition of ribavirin must be further studied.
In this large, prospective observational cohort study, the oral, interferon-free combination of 
simeprevir plus sofosbuvir for 12 weeks was associated with high rates of SVR and low 
rates of treatment discontinuation. This represents one of the first applications of a highly 
effective HCV regimen outside clinical trials; consequently, many patients treated had 
relatively urgent medical need for therapy due to advanced liver disease and/or the failure of 
all available treatment options. In this context, these data provide evidence that such 
regimens will translate effectively from the trial setting to clinical practice. Additional 
research is needed to understand which patients may benefit from different treatment 
regimens or longer treatment durations.
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Center, Tel Hashomer, Israel; J. Bredfeldt, Virginia Mason Medical Center, Seattle, WA; 
R.S. Brown, Columbia University Medical Center, New York, NY; R.T. Chung, 
Massachusetts General Hospital, Boston, MA; J. Darling, University of North Carolina at 
Chapel Hill, Chapel Hill, NC; W. Harlan, Asheville Gastroenterology, Asheville, NC; A. M. 
Di Bisceglie, Saint Louis University, Saint Louis, MO; R. C. Dickson, Dartmouth-Hitchcock 
Medical Center, Lebanon, NH; H. A. Elbeshbeshy, Baptist Medical Center, Oklahoma City, 
OK; G. Everson, University of Colorado, Aurora, CO; J. Feld, University Health Network- 
Toronto, Toronto, ON- Canada; J. M. Fenkel, Thomas Jefferson University, Philadelphia, 
PA; M. W. Fried, University of North Carolina at Chapel Hill, Chapel Hill, NC; J. Galati, 
Research Specialists of Texas, Houston, TX; S. C. Gordon, Henry Ford Hospital, Detroit, 
MI; M. Hassan, University of Minnesota, Minneapolis, MN; T.N. Hawkins, Southwest 
CARE Center, Sante Fe, NM; F. Hinestrosa, Orlando Immunology Center, Orlando, FL; I. 
M. Jacobson, Weill Cornell, New York City, NY; C. A. Kerr, Hudson River Health Care, 
Peekskill, NY; A. Kuo, University of California-San Diego, San Diego, CA; P. Y. Kwo, 
Indiana University, Indianapolis, IN; J. Levitsky, Northwestern University Feinberg School 
of Medicine, Chicago, IL; J. Lim, Yale University, New Haven, CT; A.S. Lok, University of 
Michigan, Ann Harbor, MI; M. Mailliard, University of Nebraska, Omaha, NE; M.P. 
Manns, Hannover Medical School, Hannover, Germany; G. Morelli, University of Florida, 
Gainesville, FL; A. J. Muir, Duke University, Durham, NC; D. Nelson, University of 
Florida, Gainesville, FL; J. G. O’Leary, Baylor University Medical Center, Dallas, TX; B. 
L. Pearlman, Atlanta Medical Center, Atlanta, GA; P. Pockros, Scripps Health, La Jolla, 
CA; A. Ramani, Mountain View Medical, Catskill, NY; N. Reau, University of Chicago, 
Chicago, IL; K. R. Reddy, University of Pennsylvania, Philadelphia, PA; E. R. Schiff, 
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University of Miami, Miami, FL; K. E. Sherman, University of Cincinnati, Cincinnati, OH; 
M.L. Shiffman, Liver Institute of Virginia, Richmond, VA; C. Smith, University of 
Minnesota, Minneapolis, MN; J. R. Spivey, Emory University, Atlanta, GA; R. K. Sterling, 
Virginia Commonwealth University, Richmond, VA; M. S. Sulkowski, Johns Hopkins, 
Baltimore, MD; G. Szabo, University of Massachusetts, Worcester, MA; N. A. Terrault, 
University of California-San Francisco, San Francisco, CA; C. Trautwein, RWTH 
University Hospital, Aachen, Germany; H. E. Vargas, Mayo Clinic, Phoenix, AZ; K. Watts, 
Mayo Clinic, Rochester, MN; A. Williams, Liver Wellness Center, Little Rock, AR.; S. 
Zeuzem, Goethe University Hospital, Frankfurt, Germany.
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Figure 1. 
a. Unadjusted SVR12, multiply imputed for patients treated with simeprevir plus sofosbuvir 
with or without ribavirin
b. Unadjusted SVR12, multiply imputed for patients treated with simeprevir plus sofosbuvir 
with ribavirin
c. Unadjusted SVR12, multiply imputed for patients treated with simeprevir plus sofosbuvir 
without ribavirin
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Figure 2. 
Model adjusted estimates of SVR12 among patients treated with simeprevir plus sofosbuvir 
with or without ribavirin.
Population: patients which completed a full course of treatment or prematurely discontinued 
treatment for virological reasons.
Adjusted SVR12 estimates derived from a logistic regression model which simultaneously 
adjusted for regimen, subtype (1a versus 1b), cirrhosis status, previous treatment experience, 
prior PI failure, history of prior decompensation, sex, age, and baseline chemistry measures 
of albumin, aspartate aminotransferase, creatinine, HCV RNA, HGB, and total bilirubin.
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Figure 3. 
Odds ratio estimates from logistic regression models of SVR12 and baseline factors for 
patients treated with simeprevir plus sofosbuvir with or without ribavirin.
Odds ratios are adjusted for regimen (+R v. −R), genotype (1a v. 1b), gender (male vs. 
female), and age. Each line represents a unique model. Observations are weighted with the 
inverse of probability of treatment weights (IPTW)
Population: patients which completed a full course of treatment or prematurely discontinued 
treatment for virological reasons.
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Table 1
Baseline demographics of all patients who started treatment with simeprevir plus sofosbuvir with or without 
ribavirin
Characteristic
SOF SMV
(n=667)
SOF SMV RBV
(n=169)
Total
(n=836)
Mean age (range), years 59 (20–83) 59 (29–80) 59 (20–83)
    18–39 23 (3.4) 6 (3.6) 29 (3.5)
    40–64 470 (70.5) 133 (78.7%) 603 (72.1)
    65+ 174 (26.1) 30 (17.8) 204 (24.4)
Male sex, n (%) 405 (60.7) 104 (61.5) 509 (60.9)
Race, n (%)
  White 504 (75.6) 134 (79.3) 638 (76.3)
  Black 88 (13.2) 24 (14.2) 112 (13.4)
  Asian 13 (1.9) 1 (0.6) 14 (1.7)
  Other/missing 62 (9) 10 (6) 72 (9)
Hispanic ethnicity, n (%) 31 (4.6) 11 (6.5) 42 (5.0)
Mean ALT (range), IU/l 80 (8.0–409) 86 (12.0–337) 81 (8.0–409)
Mean total bilirubin (range)
mg/dl
1.0 (0.1–8.0) 1.2 (0.2–10.7) 1.1 (0.1–10.7)
Mean albumin (range), g/dl 3.8 (1.2–5.3) 3.8 (1.8–4.7) 3.8 (1.2–5.3)
Mean hemoglobin (range), g/dl 14.0 (7.3–18.8) 14.1 (9.7–18.6) 14.0 (7.3–18.8)
Mean platelet count (range)
(×103) per µl
152 (24.0–595) 137 (24.0–521) 149 (24.0–595)
History of cirrhosis, n (%) 381 (57.1) 110 (65.1) 491 (58.7)
History of liver
decompensation (among
cirrhotics), n (%)
168 (44.1) 53 (48.2) 221 (45.0)
MELD among cirrhotics
  0–9 162 (42.5) 47 (42.7) 209 (42.6)
  10–15 101 (26.5) 21 (19.1) 122 (24.8)
  16–21 10 (2.6) 3 (2.7) 13 (2.6)
  21–39 5 (1.3) 1 (0.9) 6 (1.2)
  Pending 103 (27.0) 38 (34.5) 141 (28.7)
Presence of diabetes, n (%) 147 (22.0) 46 (27.2) 193 (23.1)
HCV genotype, n (%)
  1a 381 (57.1) 128 (75.7) 509 (60.9)
  1b 221 (33.1) 21 (12.4) 242 (28.9)
  1, subtype unspecified 65 (9.7) 20 (11.8) 85 (10.2)
  Q80K mutation tested 67 (10.0) 23 (13.6) 90 (10.7)
  Q80K mutation present 28 (4.2) 14 (8.3) 42 (5.0)
Prior HCV treatment, n (%)
  Treatment naïve 263 (39.4) 63 (37.3) 326 (39.0)
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Characteristic
SOF SMV
(n=667)
SOF SMV RBV
(n=169)
Total
(n=836)
  Prior Peg/Rbv treatment
failures
317 (47.5) 70 (41.4) 387 (46.3)
  Prior telaprevir or
boceprevir treatment failure
66 (9.9) 34 (20.1) 100 (12.0)
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Table 2
Patient disposition
SOF SMV
(n=667)
SOF SMV RBV
(n=169)
Total
(n=836)
Patient disposition during treatment, n (%)
  Completed therapy 648 (97.2) 163 (96.4) 811 (97.0)
  Discontinued therapy early 19 (2.8) 6 (3.6) 25 (3.0)
    Adverse event 13 (1.9) 4 (2.4) 17 (2.0)
    Lack of efficacy 1 (0.1) 0 (0.0) 1 (0.1)
    Withdrawal by subject 1 (0.1) 0 (0.0) 1 (0.1)
    Loss to follow up during treatment 1 (0.1) 1 (0.6) 2 (0.2)
    Other 3 (0.4) 1 (0.6) 4 (0.5)
Completed SVR 12 Follow-up 639 (96) 163 (98) 802 (96)
    Lost to post treatment follow-up* 21(3) 9 (5) 30 (4)
HCV RNA result not available** 28 (4) 6 (4) 34 (4)
*
Included in the “Completed SVR12 follow up”
**
HCV RNA result not yet available as of last follow-up appointment
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Table 4
Safety profile
SOF SMV
(n=667)
SOF SMV RBV
(n=169)
Total
(n=836)
Most common Adverse Events, n (%)
    Fatigue 162 (24.3) 60 (35.5) 222 (26.6)
    Headache 106 (15.9) 31 (18.3) 137 (16.4)
    Nausea 90 (13.5) 32 (18.9) 122 (14.7)
    Influenza like illness 73 (10.9) 20 (11.8) 93 (11.1)
    Rash/ Pruritus 60 (9.0) 27 (16.0) 87 (10.4)
    Insomnia 53 (8.0) 28 (16.6) 81 (9.7)
    Pruritus 53 (8.0) 27 (16.0) 80 (9.6)
    Anaemia 8 (1.2) 50 (29.6) 58 (6.9)
    Photosensitivity reaction 45 (6.8) 13 (7.7) 58 (6.9)
Total patients with any AE 499 (74.81) 150 (88.76) 649 (77.63)
Anemia
AE Anemia, n (%) 8 (1.2) 50 (29.6) 58 (6.9)
SAE Anemia, n (%) 1 (0.2) 0 (0.0) 1 (0.1)
Hemoglobin change, delta mean (range) −0.4 (−6.0,+5.1) −2.1 (−5.7,+1.3) −0.8 (−6.0,+5.1)
Ribavirin dose reduction/ interruption 0 (0.0) 35 (20.7) 35 (4.2)
Ribavirin discontinuation 0 (0.0) 10 (5.9) 10 (1.2)
Erythropoietin use 0 (0.0) 9 (5.3) 9 (1.1)
Blood transfusion 5 (0.7) 5 (3.0) 10 (1.2)
Most common Serious Adverse Events, n (%)
    Decompensating events 9 (1.4) 2 (1.2) 10 (1.2)
    Infections and infestations 8 (1.2) 1 (0.6) 9 (1.1)
    Cardiac failure 4 (0.6) 0 (0.0) 4 (0.5)
    Gastrointestinal hemorrhage 3 (0.5) 1 (0.6) 4 (0.5)
    Arrhythmia 2 (0.3) 1 (0.6) 3 (0.4)
    Abdominal pain 2 (0.3) 0 (0.0) 2 (0.2)
    Renal failure acute 0 (0.0) 2 (1.2) 2 (0.2)
    Dyspnea 2 (0.3) 0 (0.0) 2 (0.2)
    Thromboembolic events 2 (0.3) 0 (0.0) 2 (0.2)
Total patients with any SAE 32 (4.80) 12 (7.10) 44 (5.26)
Creatinine changea, delta mean (range)mg/dL 0.0 (−5.6,+0.9) 0.0 (−0.8,+0.8) 0.0 (−5.6,+0.9)
Total Bilirubin changea, delta mean (range) mg/dL 0.1 (−3.3,+3.4) 0.5 (−10.1,+8.3) 0.2 (−10.1,+8.3)
Deaths, n 4 (0.6) 1 (0.6) 5 (0.6)
a
The change in creatinine and bilirubin is defined as the change in value from study initiation to the end of treatment (EOT or the date closest to 
EOT, not exceeding 2 weeks post EOT and not preceding 8 weeks post start of treatment).
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